Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,954 DKK | +2.04% | -2.32% | -9.07% |
Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.07% | 17.85B | |
-2.32% | 103B | |
+0.40% | 95.71B | |
+2.39% | 22.02B | |
-16.75% | 20.9B | |
-42.83% | 16.21B | |
-15.16% | 15.52B | |
+3.64% | 13.86B | |
+34.69% | 12.04B | |
-25.83% | 8.08B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S : HC Wainwright Adjusts Genmab A/S' Price Target to $49 from $44, Keeps Buy Rating